Sagimet Biosciences (SGMT) lost ~9% in the premarket on Thursday after Ascletis Pharma (ASCLF), its Chinese licensing partner for the acne candidate denifanstat (ASC40), announced initial data from a late-stage trial for the once-daily therapy.
The Phase 3 open-label study
